<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00362</drugbank-id>
  <drugbank-id>APRD01301</drugbank-id>
  <name>Anidulafungin</name>
  <description>Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin.</description>
  <cas-number>166663-25-8</cas-number>
  <unii>9HLM53094I</unii>
  <average-mass>1140.2369</average-mass>
  <monoisotopic-mass>1139.506293945</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A539</ref-id>
        <pubmed-id>17316149</pubmed-id>
        <citation>Cappelletty D, Eiselstein-McKitrick K: The echinocandins. Pharmacotherapy. 2007 Mar;27(3):369-88.</citation>
      </article>
      <article>
        <ref-id>A540</ref-id>
        <pubmed-id>16117974</pubmed-id>
        <citation>Vazquez JA: Anidulafungin: a new echinocandin with a novel profile. Clin Ther. 2005 Jun;27(6):657-73.</citation>
      </article>
      <article>
        <ref-id>A541</ref-id>
        <pubmed-id>20606829</pubmed-id>
        <citation>Grover ND: Echinocandins: A ray of hope in antifungal drug therapy. Indian J Pharmacol. 2010 Feb;42(1):9-11. doi: 10.4103/0253-7613.62396.</citation>
      </article>
      <article>
        <ref-id>A542</ref-id>
        <pubmed-id>17044802</pubmed-id>
        <citation>Vazquez JA: The safety of anidulafungin. Expert Opin Drug Saf. 2006 Nov;5(6):751-8.</citation>
      </article>
      <article>
        <ref-id>A543</ref-id>
        <pubmed-id>19877741</pubmed-id>
        <citation>Menichetti F: Anidulafungin, a new echinocandin: effectiveness and tolerability. Drugs. 2009;69 Suppl 1:95-7. doi: 10.2165/11315570-000000000-00000.</citation>
      </article>
      <article>
        <ref-id>A544</ref-id>
        <pubmed-id>16779750</pubmed-id>
        <citation>Vazquez JA, Sobel JD: Anidulafungin: a novel echinocandin. Clin Infect Dis. 2006 Jul 15;43(2):215-22. Epub 2006 Jun 9.</citation>
      </article>
      <article>
        <ref-id>A545</ref-id>
        <pubmed-id>19113794</pubmed-id>
        <citation>Estes KE, Penzak SR, Calis KA, Walsh TJ: Pharmacology and antifungal properties of anidulafungin, a new echinocandin. Pharmacotherapy. 2009 Jan;29(1):17-30. doi: 10.1592/phco.29.1.17.</citation>
      </article>
      <article>
        <ref-id>A546</ref-id>
        <pubmed-id>19877740</pubmed-id>
        <citation>Morace G, Borghi E, Iatta R, Montagna MT: Anidulafungin, a new echinocandin: in vitro activity. Drugs. 2009;69 Suppl 1:91-4. doi: 10.2165/11315560-000000000-00000.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Scott Jenkins, Gary Liversidge, Deborah Neville, "Nanoparticulate Anidulafungin Compositions and Methods for Making the Same." U.S. Patent US20090238867, issued September 24, 2009.</synthesis-reference>
  <indication>For use in the treatment of the following fungal infections: Candidemia and other forms of &lt;i&gt;Candida&lt;/i&gt; infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis.</indication>
  <pharmacodynamics>Anidulafungin is a semi-synthetic lipopeptide synthesized from a fermentation product of &lt;i&gt;Aspergillus nidulans&lt;/i&gt;. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-&amp;beta;-D-glucan, an essential component of fungal cell walls. Anidulafungin is active in vitro against many &lt;i&gt;Candida&lt;/i&gt;, as well as some &lt;i&gt;Aspergillus&lt;/i&gt;. Like other echinocandins, anidulafungin is not active against &lt;i&gt;Cryptococcus neoformans&lt;/i&gt;, &lt;i&gt;Trichosporon&lt;/i&gt;, &lt;i&gt;Fusarium&lt;/i&gt;, or zygomycetes.</pharmacodynamics>
  <mechanism-of-action>Anidulafungin is a semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-&amp;beta;-D-glucan, an essential component of the fungal cell wall, ultimately leading to osmotic instability and cell death.</mechanism-of-action>
  <toxicity>During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day).</toxicity>
  <metabolism>Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 (CYP450) isoenzymes. Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity.</metabolism>
  <absorption/>
  <half-life>40-50 hours</half-life>
  <protein-binding>84%</protein-binding>
  <route-of-elimination>Less than 1% of the administered radioactive dose was excreted in the urine. Anidulafungin is not hepatically metabolized.</route-of-elimination>
  <volume-of-distribution>* 30 to 50 L</volume-of-distribution>
  <clearance>* 1 L/h</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds.</description>
    <direct-parent>Oligopeptides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organic acids and derivatives</superclass>
    <class>Carboxylic acids and derivatives</class>
    <subclass>Amino acids, peptides, and analogues</subclass>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>Alkanolamines</alternative-parent>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Aromatic alcohols</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Benzamides</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Biphenyls and derivatives</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Cyclic peptides</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Lactams</alternative-parent>
    <alternative-parent>Macrolactams</alternative-parent>
    <alternative-parent>N-acyl-alpha amino acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>P-terphenyls</alternative-parent>
    <alternative-parent>Phenol ethers</alternative-parent>
    <alternative-parent>Phenoxy compounds</alternative-parent>
    <alternative-parent>Polyols</alternative-parent>
    <alternative-parent>Pyrrolidines</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Alkanolamine</substituent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Alpha-amino acid or derivatives</substituent>
    <substituent>Alpha-oligopeptide</substituent>
    <substituent>Aromatic alcohol</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzamide</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Benzoic acid or derivatives</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>Biphenyl</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Cyclic alpha peptide</substituent>
    <substituent>Ether</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Lactam</substituent>
    <substituent>Macrolactam</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-acyl-alpha amino acid or derivatives</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Para-terphenyl</substituent>
    <substituent>Phenol</substituent>
    <substituent>Phenol ether</substituent>
    <substituent>Phenoxy compound</substituent>
    <substituent>Polyol</substituent>
    <substituent>Pyrrolidine</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Terphenyl</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english/german" coder="inn/ban/usan">Anidulafungin</synonym>
    <synonym language="spanish" coder="inn">Anidulafungina</synonym>
    <synonym language="french" coder="inn">Anidulafungine</synonym>
    <synonym language="latin" coder="inn">Anidulafunginum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Eraxis</name>
      <labeller>Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0049-1010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-05-15</started-marketing-on>
      <ended-marketing-on>2007-05-15</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>50 mg/15mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eraxis</name>
      <labeller>Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0049-0115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-05-15</started-marketing-on>
      <ended-marketing-on>2007-05-15</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength>100 mg/30mL</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eraxis</name>
      <labeller>Roerig</labeller>
      <ndc-id/>
      <ndc-product-code>0049-0114</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>50 mg/15mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021632</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eraxis</name>
      <labeller>Roerig</labeller>
      <ndc-id/>
      <ndc-product-code>0049-0116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-02-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>100 mg/30mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021632</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Eraxis</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02330695</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-01-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>100 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Eraxis</name>
      <labeller>Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02302160</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-01-25</started-marketing-on>
      <ended-marketing-on>2013-07-19</ended-marketing-on>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>100 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Gd-anidulafungin</name>
      <labeller>Genmed A Division Of Pfizer Canada Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02441683</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Ecalta</name>
      <company>Pfizer</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Eraxis</name>
      <ingredients>Anidulafungin</ingredients>
    </mixture>
    <mixture>
      <name>Eraxis</name>
      <ingredients>Anidulafungin</ingredients>
    </mixture>
    <mixture>
      <name>Eraxis</name>
      <ingredients>Anidulafungin</ingredients>
    </mixture>
    <mixture>
      <name>Eraxis</name>
      <ingredients>Anidulafungin</ingredients>
    </mixture>
    <mixture>
      <name>Eraxis</name>
      <ingredients>Anidulafungin</ingredients>
    </mixture>
    <mixture>
      <name>Eraxis</name>
      <ingredients>Anidulafungin</ingredients>
    </mixture>
    <mixture>
      <name>Gd-anidulafungin</name>
      <ingredients>Anidulafungin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Ben Venue Laboratories Inc.</name>
      <url>http://www.benvenue.com</url>
    </packager>
    <packager>
      <name>Pfizer Inc.</name>
      <url>http://www.pfizer.com</url>
    </packager>
    <packager>
      <name>Pharmacia Inc.</name>
      <url>http://www.pharmaciaupjohn.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Vicuron pharmaceuticals inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Eraxis(water dil) 50 mg vial</description>
      <cost currency="USD">108.0</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>Eraxis(water dil) 100 mg vial</description>
      <cost currency="USD">216.0</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antifungal Agents</category>
      <mesh-id>D000935</mesh-id>
    </category>
    <category>
      <category>Antiinfectives for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antimycotics for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Echinocandin Antifungal</category>
      <mesh-id/>
    </category>
    <category>
      <category>Echinocandins</category>
      <mesh-id>D054714</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Peptides, Cyclic</category>
      <mesh-id>D010456</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Candida albicans and other yeasts</affected-organism>
    <affected-organism>Aspergillis, Candida and other fungi</affected-organism>
    <affected-organism>Candida parapsilosis</affected-organism>
    <affected-organism>Coolia tropicalis</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>100 mg/30mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>50 mg/15mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength>100 mg/30mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intravenous</route>
      <strength>50 mg/15mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>100 mg</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="J02AX06">
      <level code="J02AX">Other antimycotics for systemic use</level>
      <level code="J02A">ANTIMYCOTICS FOR SYSTEMIC USE</level>
      <level code="J02">ANTIMYCOTICS FOR SYSTEMIC USE</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>08:14.16</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00362.pdf?1265922809</fda-label>
  <patents>
    <patent>
      <number>7198796</number>
      <country>United States</country>
      <approved>2007-04-03</approved>
      <expires>2022-06-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6384013</number>
      <country>United States</country>
      <approved>2002-05-07</approved>
      <expires>2012-03-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2362481</number>
      <country>Canada</country>
      <approved>2008-11-04</approved>
      <expires>2020-03-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2091663</number>
      <country>Canada</country>
      <approved>2007-10-30</approved>
      <expires>2013-03-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5965525</number>
      <country>United States</country>
      <approved>1999-10-12</approved>
      <expires>2020-02-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6960564</number>
      <country>United States</country>
      <approved>2005-11-01</approved>
      <expires>2021-04-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7709444</number>
      <country>United States</country>
      <approved>2010-05-04</approved>
      <expires>2021-04-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The therapeutic efficacy of Dicoumarol can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The therapeutic efficacy of Phenindione can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The therapeutic efficacy of Warfarin can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The therapeutic efficacy of Coumarin can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The therapeutic efficacy of Fluindione can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The therapeutic efficacy of Clorindione can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The therapeutic efficacy of Diphenadione can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The therapeutic efficacy of Tioclomarol can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Anidulafungin.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.87</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.3</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.64e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-18-yl]-4-[4'-(pentyloxy)-[1,1'-biphenyl]-4-yl]benzamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-18-yl]-4-[4'-(pentyloxy)-[1,1'-biphenyl]-4-yl]benzamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>1140.2369</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>1139.506293945</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>[H][C@]1(NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C1=O)NC(=O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C58H73N7O17</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>JHVAMHSQVVQIOT-MFAJLEFUSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>377.42</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>292.29</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>122.78</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>17</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>9.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3.5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Practically insoluble</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.9</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20177</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>55346</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>166548</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505616</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D03211</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>145752</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50417554</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164742938</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000546</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Anidulafungin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL264241</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/anidulafungin.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004669</id>
      <name>1,3-beta-glucan synthase component FKS1</name>
      <organism>Aspergillus niger (strain CBS 513.88 / FGSC A1513)</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A784</ref-id>
            <pubmed-id>19724014</pubmed-id>
            <citation>Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep  1.</citation>
          </article>
          <article>
            <ref-id>A787</ref-id>
            <pubmed-id>16960253</pubmed-id>
            <citation>Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703.</citation>
          </article>
          <article>
            <ref-id>A788</ref-id>
            <pubmed-id>16990627</pubmed-id>
            <citation>Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20.</citation>
          </article>
          <article>
            <ref-id>A16924</ref-id>
            <pubmed-id>18473501</pubmed-id>
            <citation>Ponton J: [The fungal cell wall and the mechanism of action of anidulafungin]. Rev Iberoam Micol. 2008 Jun;25(2):78-82.</citation>
          </article>
          <article>
            <ref-id>A16925</ref-id>
            <pubmed-id>19463275</pubmed-id>
            <citation>Quindos G, Eraso E, Javier Carrillo-Munoz A, Canton E, Peman J: [In vitro antifungal activity of micafungin]. Rev Iberoam Micol. 2009 Mar 31;26(1):35-41. doi: 10.1016/S1130-1406(09)70006-3. Epub 2009 May 7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="A2QLK4" source="Swiss-Prot">
        <name>1,3-beta-glucan synthase component FKS1</name>
        <general-function>1,3-beta-d-glucan synthase activity</general-function>
        <specific-function>Catalytic subunit of the 1,3-beta-glucan synthase. Synthesizes 1,3-beta-glucan, a major structural component of the cell wall. Involved in cell wall synthesis, maintenance and cell wall remodeling (By similarity).</specific-function>
        <gene-name>fksA</gene-name>
        <locus/>
        <cellular-location>Mitochondrion</cellular-location>
        <transmembrane-regions>487-507
525-545
564-584
591-611
655-675
707-727
728-748
1329-1349
1386-1406
1473-1493
1497-1517
1588-1608
1630-1650
1666-1686
1701-1721
1766-1786
1826-1846</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>216972.8</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="425011">Aspergillus niger (strain CBS 513.88 / FGSC A1513)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>A2QLK4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FKS1_ASPNC</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,3-beta-D-glucan-UDP glucosyltransferase</synonym>
          <synonym>2.4.1.34</synonym>
          <synonym>fks1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0013251|1,3-beta-glucan synthase component FKS1
MSGYPAGHYEDGYGHQEHGGDAYYQDEHGQAYYDPNDYGDSYYDRGNYYNAEGGQAYGQE
GGYYDAGHQDDYYGDQYYDQGNGAPRGRRRGDSEEDSETFSDFTMRSETARAADMDYYGR
GDERYNSYADSQYAGRGYNGYRPPSSQVSYGANRSSGASTPVYGMDYGSALPGGPRSREP
YPAWASDGQVPVSKEEIEDIFIDLVNKFGFQRDSMRNMYDHLMTQLDSRASRMTPNQALL
SLHADYIGGDNANYRRWYFAAHLDLDDAVGFANMKLGKADRKTRKARKAAKAAAQQNPEN
VEENLEAMEGDNSLEAAVYRWKSRMNRMSPHDRVRQLALYMLCWGEANQVRYMPECICFI
FKCADDYYSSPECQSRVEPVEEFTYLNEIITPLYQFCRDQGYEILDGKYVRRERDHEKII
GYDDMNQLFWYPEGIERISFEDKTRLVDVPPAERWTKLKDVDWKKAFFKTYRETRSWFHM
ITNFNRIWVIHLGAFWFFTAYNAPTLYTKNYQQQLDNKPAGSKYWSAVGFGGALVGLIQI
LATLCEWMYVPRRWAGAQHLSKRLMFLIAVFIVNLAPGVVVFGFNNVLSETICLIIGIVH
FFIALATFFFFSVMPLGGLFGSYLKKHGRQYVASQTFTASYPRLNGNDMWMSYGLWICVF
GAKLVESYFFLTLSLKDPMRILSPMRIHQCAGVTYIPNSLCHAQPQILLGLMMFMDLTLF
FLDSYLWYVICNTIFSVARSFYLGVSIWSPWRNIFSRLPKRIYSKVLATTDMEIKYKPKV
LISQVWNAIIISMYREHLLAIDHVQKLLYHQVPSEQEGKRTLRAPTFFVSQEDQSFKTEF
FPAGSEAERRISFFAQSVATPMPEPLPVDNMPTFTVLIPHYGEKILLSLREIIREDEPYS
RVTLLEYLKQLHPHEWDCFVKDTKILADETSQLNGEPEKNEKDAQKSKIDDLPFYCIGFK
SAAPEYTLRTRIWSSLRSQTLYRTISGFMNYSRAIKLLYRVENPEVVQMFGGNSEKLERE
LERMARRKFKICVSMQRYAKFNKEERENTEFLLRAYPDLQIAYLDEEPPANEGEEPRLYS
ALIDGHCELLDNGMRKPKFRIQLSGNPILGDGKSDNQNHSIIFYRGEYIQVIDANQDNYL
EECLKIRSVLAEFEELTTDNVSPYTPGIATEAETPVAILGAREYIFSENVGVLGDVAASK
EQTFGTLFARTLAQIGGKLHYGHPDFLNGIFMTTRGGISKAQKGLHLNEDIYAGMTALCR
GGRIKHCEYFQCGKGRDLGFGSILNFTTKIGTGMGEQMLSREYYYLGTQLPLDRFLSFYY
AHPGFHLNNMFIMLSVQMFMIVLINLGALKHETITCRYNSNLPITDPLRPTYCADLTPII
AWVNRCVVSIFIVFFISFVPLAVQELTERGLWRMATRLAKHFGSFSFMFEVFVCQIYANA
VHQNLSFGGARYIGTGRGFATARIPFGVLYSRFAGPSIYAGSRLLLMLLFATSTVWTPAL
IWFWVSLLALCISPFLFNPHQFAWHDFFIDYRDYIRWLSRGNSRSHASSWIAFCRLSRTR
LTGYKRKLLGVPSEKGSGDVPRAKFTNIFFSEIIAPLVQVAVTLVPYLYINSRTGISNDN
ERASNAVVRIAIVAFGPIGVNAGVSGMFFGMACCMGPIFGMCCKKFGAVLAAIAHAIAVI
ILLVIFEVMFFLESWSWPRMVLGMISAAAIQRFIYKLIISLALTREFKHDQSNIAWWTGK
WYNMGWHSLSQPGREFLCKITELGYFSADFVLGHILLFVMLPALCIPYVDKFHSVILFWL
RPSRQIRPPIYSLKQSKLRKRRVVRFAILYFTMLVLFLILLIAPLVARDEGISVNLNIMS
LMQPLDTDNNDTISSYTGNGLPVGYSAWTPSAASASA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013252|1,3-beta-glucan synthase component FKS1 (fksA)
ATGTCAGGCTATCCAGCAGGGCATTACGAGGATGGCTACGGCCACCAGGAGCATGGGGGC
GATGCGTACTACCAGGACGAACATGGCCAGGCTTATTACGATCCTAACGATTACGGTGAC
AGCTATTATGATAGAGGCAATTATTACAACGCAGAAGGAGGTCAGGCATATGGCCAAGAA
GGTGGTTACTACGATGCTGGTCACCAGGATGACTACTACGGTGACCAGTACTATGACCAA
GGAAATGGTGCCCCCCGCGGAAGACGCCGTGGAGATTCTGAGGAGGATTCGGAGACCTTT
AGCGATTTCACCATGAGGTCAGAGACTGCTCGAGCTGCGGATATGGATTACTATGGCCGT
GGAGACGAACGTTACAACAGTTATGCCGACAGCCAGTATGCTGGTCGTGGATACAACGGA
TACCGGCCGCCATCTTCGCAGGTCTCGTATGGCGCCAACCGATCATCTGGCGCTTCGACA
CCCGTATACGGCATGGACTACGGAAGCGCCCTTCCTGGTGGACCGCGTTCTCGGGAGCCG
TACCCAGCCTGGGCATCGGATGGTCAGGTCCCTGTCTCCAAGGAGGAAATCGAAGATATC
TTCATTGACTTGGTCAACAAATTCGGTTTCCAGAGGGACAGCATGCGCAACATGTATGAC
CACCTGATGACACAGTTGGACTCCCGGGCCTCCAGAATGACGCCCAACCAAGCCCTTCTG
TCTCTGCACGCAGACTACATTGGTGGTGACAATGCCAACTACCGCCGTTGGTATTTTGCT
GCCCATCTGGATTTGGACGATGCCGTGGGATTCGCCAACATGAAGCTGGGCAAAGCAGAC
CGGAAGACCAGGAAAGCTCGCAAAGCGGCCAAGGCGGCAGCACAGCAGAACCCTGAAAAC
GTCGAGGAGAACCTGGAGGCCATGGAAGGCGACAACAGCCTGGAAGCCGCTGTTTACAGG
TGGAAGAGCCGCATGAACCGCATGTCCCCGCATGATCGTGTGCGCCAATTGGCTCTGTAC
ATGCTGTGCTGGGGTGAAGCTAACCAGGTCCGGTACATGCCTGAGTGCATTTGCTTCATC
TTCAAGTGTGCGGATGATTACTACAGCTCCCCTGAATGCCAGAGCCGGGTTGAGCCGGTG
GAGGAATTCACTTACCTGAATGAGATCATTACCCCCCTCTATCAGTTCTGCCGTGACCAG
GGTTACGAAATCTTGGATGGCAAGTATGTTCGCCGCGAGCGTGATCACGAGAAGATCATC
GGATACGATGATATGAACCAGCTTTTCTGGTACCCCGAGGGTATCGAACGCATCTCATTC
GAGGATAAGACTCGTCTTGTCGATGTCCCCCCAGCTGAAAGATGGACCAAGTTGAAGGAC
GTCGACTGGAAGAAAGCATTCTTCAAGACGTACAGAGAGACTCGGTCCTGGTTCCACATG
ATCACCAACTTCAACCGTATCTGGGTTATTCACCTGGGTGCTTTCTGGTTCTTCACTGCT
TATAACGCCCCCACCTTGTATACCAAGAACTACCAGCAGCAGCTGGACAATAAGCCCGCT
GGTTCAAAGTATTGGTCTGCTGTCGGTTTTGGTGGTGCCCTGGTTGGATTAATTCAGATC
TTGGCAACGCTCTGTGAGTGGATGTACGTGCCTCGCCGGTGGGCAGGTGCTCAGCATCTC
AGCAAGCGTCTTATGTTCCTTATCGCCGTTTTCATTGTCAATCTTGCTCCTGGTGTCGTG
GTCTTCGGTTTCAACAATGTTCTCAGTGAGACAATCTGCCTCATCATTGGTATCGTCCAC
TTCTTCATTGCTCTGGCCACGTTCTTCTTTTTCTCCGTCATGCCTCTTGGAGGTCTGTTC
GGCAGTTACCTGAAGAAGCACGGCCGTCAATATGTGGCCAGTCAGACATTCACGGCGAGC
TACCCTCGCCTGAATGGCAACGACATGTGGATGTCTTATGGTCTGTGGATCTGTGTTTTC
GGTGCGAAGCTGGTCGAGTCTTACTTCTTCCTGACTCTGTCATTGAAGGATCCCATGCGT
ATCTTGTCGCCGATGCGTATCCATCAGTGTGCTGGTGTGACATACATCCCGAACAGCCTT
TGCCACGCCCAGCCTCAGATTCTGCTGGGTCTGATGATGTTCATGGATTTGACTCTTTTC
TTCCTGGATAGTTATCTGTGGTATGTCATTTGTAACACCATCTTCTCGGTGGCTCGGTCC
TTCTACCTGGGTGTCTCCATCTGGTCGCCCTGGAGAAACATCTTCTCTCGCCTACCGAAG
CGTATCTATTCGAAGGTCTTGGCTACGACCGACATGGAGATCAAGTACAAGCCCAAGGTG
CTCATTTCCCAAGTTTGGAACGCCATCATCATCTCCATGTACCGTGAGCATCTGCTGGCG
ATTGATCACGTCCAGAAGTTGCTTTACCACCAGGTTCCCTCCGAACAGGAGGGCAAGCGT
ACCCTGCGGGCTCCTACCTTCTTCGTTTCGCAGGAAGACCAGTCCTTCAAGACTGAGTTC
TTCCCCGCGGGTAGTGAGGCTGAGCGCCGTATCTCCTTCTTTGCCCAGTCGGTCGCTACC
CCCATGCCTGAGCCTCTTCCGGTTGACAACATGCCCACTTTCACTGTCCTTATCCCCCAT
TACGGAGAGAAGATTCTGCTGTCGTTGCGTGAAATCATTCGTGAGGATGAGCCGTACTCT
CGCGTTACTCTCCTGGAATACCTGAAACAGCTCCACCCCCACGAGTGGGACTGCTTCGTC
AAGGACACAAAGATTCTGGCTGATGAGACCTCACAACTCAACGGCGAACCCGAGAAGAAC
GAGAAGGATGCGCAGAAGAGCAAGATCGACGACCTTCCCTTCTATTGCATCGGTTTCAAG
TCTGCCGCTCCCGAATACACGCTCCGTACCCGTATCTGGTCCTCTCTGCGCTCTCAGACC
CTGTACAGAACCATTTCCGGTTTCATGAACTACAGCAGGGCCATCAAGCTCCTTTACCGT
GTCGAAAACCCCGAGGTCGTCCAGATGTTTGGTGGTAACTCCGAGAAGCTCGAACGTGAG
CTTGAAAGGATGGCGCGCCGCAAGTTCAAGATCTGTGTCTCAATGCAACGTTACGCCAAG
TTCAACAAGGAAGAGCGTGAAAACACCGAGTTCCTTCTCCGTGCCTACCCTGATCTCCAA
ATCGCTTACCTTGACGAGGAACCCCCTGCCAATGAGGGTGAGGAGCCCCGCTTGTACTCG
GCTTTGATTGATGGACACTGTGAGCTCCTCGACAACGGAATGCGCAAGCCGAAGTTCAGA
ATTCAGCTCTCCGGAAACCCTATCCTGGGTGACGGCAAGTCCGATAACCAGAACCACTCT
ATCATCTTCTACCGCGGTGAATACATCCAGGTCATTGACGCTAACCAGGATAACTACCTG
GAGGAGTGTCTCAAGATCCGTAGCGTTCTGGCTGAGTTCGAAGAACTTACCACCGACAAT
GTCTCGCCCTACACTCCTGGTATTGCCACCGAAGCTGAGACCCCAGTCGCCATTCTCGGT
GCTCGTGAATACATTTTCTCTGAGAATGTTGGTGTTCTTGGTGACGTTGCTGCCAGTAAG
GAACAGACGTTCGGTACCCTGTTTGCTCGTACCCTTGCGCAGATTGGTGGAAAGCTGCAT
TATGGTCACCCTGATTTCCTAAACGGTATCTTCATGACGACGCGTGGTGGTATCTCCAAG
GCTCAGAAGGGTCTCCACCTGAACGAGGATATTTATGCTGGTATGACTGCTTTGTGCCGT
GGTGGACGCATCAAGCATTGCGAGTACTTCCAGTGTGGTAAGGGTCGTGATTTGGGTTTC
GGCTCCATTCTGAACTTCACAACCAAGATTGGTACTGGTATGGGTGAGCAGATGCTGTCC
AGAGAGTACTACTATCTCGGAACACAGCTGCCCCTCGATCGCTTCCTGTCTTTCTACTAT
GCTCACCCTGGTTTCCATCTTAACAACATGTTCATTATGTTGTCTGTGCAGATGTTCATG
ATCGTTCTGATCAACCTTGGTGCTCTGAAGCATGAGACTATTACATGCCGTTACAACTCG
AACCTGCCCATTACTGACCCTCTGCGTCCCACGTACTGTGCTGATCTTACCCCCATTATC
GCCTGGGTGAACCGTTGCGTCGTTTCCATCTTCATTGTGTTCTTCATCTCCTTCGTTCCC
CTGGCCGTCCAGGAATTGACTGAGAGGGGTCTTTGGCGCATGGCTACTCGTCTGGCCAAG
CACTTTGGTTCCTTCTCCTTCATGTTCGAGGTGTTTGTCTGCCAAATCTACGCCAATGCT
GTTCACCAGAACCTTTCCTTCGGCGGTGCTCGCTACATCGGTACTGGACGTGGTTTCGCT
ACGGCTCGTATCCCATTCGGTGTCTTGTACTCCCGTTTCGCTGGACCATCCATCTATGCC
GGTTCTCGTTTGCTGCTCATGCTTCTGTTTGCGACATCCACTGTCTGGACACCAGCCCTG
ATCTGGTTCTGGGTTTCTCTGCTTGCTCTCTGCATTTCCCCCTTCCTGTTCAACCCCCAC
CAGTTTGCTTGGCACGATTTCTTTATCGACTACCGCGATTACATCAGATGGCTGTCCCGT
GGTAACTCTCGCTCGCACGCTTCGTCCTGGATCGCCTTCTGCCGCCTGTCTCGTACCCGT
CTCACTGGTTACAAGCGCAAGCTTCTTGGTGTTCCTTCGGAGAAGGGATCTGGCGATGTT
CCCAGGGCCAAGTTCACGAACATTTTCTTTAGTGAGATCATTGCCCCTCTCGTCCAAGTT
GCTGTGACTTTGGTTCCTTACCTCTACATCAACTCGAGAACTGGTATCTCCAATGACAAC
GAGCGGGCGTCAAATGCCGTGGTTCGTATTGCCATCGTCGCCTTCGGTCCCATCGGTGTT
AACGCCGGTGTCTCGGGTATGTTCTTCGGTATGGCTTGCTGTATGGGTCCCATCTTTGGC
ATGTGCTGCAAGAAGTTTGGTGCAGTCCTCGCTGCTATCGCTCACGCCATCGCGGTTATT
ATCCTGCTTGTCATTTTCGAGGTCATGTTCTTCCTTGAGAGCTGGTCCTGGCCTCGCATG
GTCCTGGGAATGATTTCTGCCGCTGCAATTCAGCGCTTCATCTACAAGCTGATCATCTCC
CTCGCCCTGACCAGAGAATTCAAGCATGACCAGTCGAACATCGCTTGGTGGACCGGAAAA
TGGTACAACATGGGTTGGCACTCGCTTTCCCAGCCTGGCAGAGAATTCCTGTGCAAGATT
ACCGAGCTTGGATACTTCTCTGCCGACTTTGTCCTGGGCCATATTCTCCTCTTTGTCATG
CTTCCTGCTCTCTGCATCCCCTATGTTGACAAGTTCCACTCCGTTATCCTCTTCTGGCTG
AGGCCTAGTCGTCAAATTCGCCCTCCCATCTACTCTCTGAAGCAGTCTAAGCTCCGCAAG
AGAAGAGTTGTCCGATTTGCGATTCTGTATTTCACTATGCTGGTTCTGTTCCTCATCCTT
CTCATTGCTCCTCTGGTTGCCCGGGATGAAGGCATCAGCGTGAACCTCAACATCATGAGC
CTTATGCAGCCTCTGGATACCGACAATAACGATACCATCTCCAGTTACACTGGTAATGGT
CTCCCTGTCGGTTACTCTGCCTGGACCCCGTCCGCGGCGTCTGCATCTGCTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF14288</identifier>
            <name>FKS1_dom1</name>
          </pfam>
          <pfam>
            <identifier>PF02364</identifier>
            <name>Glucan_synthase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>1,3-beta-D-glucan synthase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1,3-beta-D-glucan synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>(1-&gt;3)-beta-D-glucan biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell wall organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>